Prolyl hydroxylase inhibitors and methods of use
View Patent ↗The present disclosure relates to HIF-1α prolyl hydroxylase inhibitors, compositions which comprise the HIF-1α prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia.
1. A method for treating anemia, comprising administering to a patient having anemia a compound having a structure:
wherein
R is selected from
i) 3-chlorophenyl; and
ii) 2,3-dihydrobenzo[1,4]dioxin-6-yl;
R 2 is selected from
i) OR 6 ; and
ii) NR 7a R 7b ;
R 6 is selected from hydrogen, methyl, and ethyl;
R 7a and R 7b are each independently selected from:
i) hydrogen; and
ii) methyl;
or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein the compound has a structure:
wherein
R 2 is selected from
i) OR 6 ; and
ii) NR 7a R 7b ;
R 6 is selected from hydrogen, methyl, and ethyl;
R 7a and R 7b are each independently selected from:
i) hydrogen; and
ii) methyl;
or a pharmaceutically acceptable salt thereof.
3. The method of claim 1 , wherein the compound has a structure:
wherein
R 2 is selected from
i) OR 6 ; and
ii) NR 7a R 7b ;
R 6 is selected from hydrogen, methyl, and ethyl;
R 7a and R 7b are each independently selected from:
i) hydrogen; and
ii) methyl;
or a pharmaceutically acceptable salt thereof.
4. The method of claim 2 , wherein the compound is selected from:
{[5-(3-Chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid methyl ester;
{[5-(3-Chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid;
5-(3-Chlorophenyl)-N-(2-amino-2-oxoethyl)-3-hydroxylpyridin-2-yl amide;
5-(3-Chlorophenyl)-N-(2-methylamino-2-oxoethyl)-3-hydroxylpyridin-2-yl amide; and
5-(3-Chlorophenyl)-N-(2-dimethylamino-2-oxoethyl)-3-hydroxylpyridin-2-yl amide;
or a pharmaceutically acceptable salt thereof.
5. The method of claim 4 , wherein the compound has a structure:
or a pharmaceutically acceptable salt thereof.
6. The method of claim 4 , wherein the compound has a structure:
or a pharmaceutically acceptable salt thereof.
7. The method of claim 4 , wherein the compound has a structure:
or a pharmaceutically acceptable salt thereof.
8. The method of claim 4 , wherein the compound has a structure:
or a pharmaceutically acceptable salt thereof.
9. The method of claim 4 , wherein the compound has a structure:
or a pharmaceutically acceptable salt thereof.
10. The method of claim 3 , wherein the compound has a structure:
or a pharmaceutically acceptable salt thereof.